shutterstock_512649

Merck KGaA to flog Allergopharma business to Dermapharm

pharmafile | February 21, 2020 | News story | Medical Communications, Sales and Marketing Allergopharma, Dermapharm, Merck KGaA, pharma 

German-based drugmaker Merck KGaA has confirmed its intention to divest its allergy business Allergopharma to Dermapharm, another German manufacturer of generics, dietary products, cosmetics and medical devices.

The business unit generated €88 million for Merck in 2018. It is currently developing a competitor to Mylan’s flagship EpiPen epinephrine autoinjector as a treatment for anaphylactic reactions.

The agreement includes Allergopharma’s therapeutic and diagnostic portfolio, but also its production site located in Reinbek, Germany.

The value of the sale was not disclosed, but Merck’s share price rose 1.34% on announcement of the news, while Dermapharm’s rose by 3.05%.

Advertisement

It was confirmed that the deal is expected to close in the second quarter of this year, subject to regulatory approval and satisfaction of closing conditions.

Matt Fellows

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

blood_test

Johnson & Johnson announces successful results from trial for myeloma treatment

Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …

Bend Bioscience adds commercial spray drying facility to Georgia site

Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …

The Gateway to Local Adoption Series

Latest content